Trial Profile
ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms ARIES-3
- Sponsors Gilead Sciences
- 19 Sep 2014 New trial record